A bispecific antibody consisting of an anti-PD-L1 antibody and an anti-TIGIT nanobody could bridge between PD-L1+ tumor cells and T/NK cells leading to simultaneous blockade of PD-L1/PD-1 and TIGIT, enhanced infiltration of cytotoxic T lymphocytes (CTLs) and NK cells; and tumor growth inhibition in a mouse model (159). This evidence concerns the gene CD274 and neoplasm.